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ABSTRACT
Objective Barrett’s oesophagus shows appearances
described as ‘intestinal metaplasia’, in structures called
‘crypts’ but do not typically display crypt architecture.
Here, we investigate their relationship to gastric glands.
Methods Cell proliferation and migration within
Barrett’s glands was assessed by Ki67 and
iododeoxyuridine (IdU) labelling. Expression of mucin
core proteins (MUC), trefoil family factor (TFF) peptides
and LGR5 mRNA was determined by
immunohistochemistry or by in situ hybridisation, and
clonality was elucidated using mitochondrial DNA
(mtDNA) mutations combined with mucin histochemistry.
Results Proliferation predominantly occurs in the
middle of Barrett’s glands, diminishing towards the
surface and the base: IdU dynamics demonstrate
bidirectional migration, similar to gastric glands.
Distribution of MUC5AC, TFF1, MUC6 and TFF2 in
Barrett’s mirrors pyloric glands and is preserved in
Barrett’s dysplasia. MUC2-positive goblet cells are
localised above the neck in Barrett’s glands, and TFF3 is
concentrated in the same region. LGR5 mRNA is
detected in the middle of Barrett’s glands suggesting a
stem cell niche in this locale, similar to that in the
gastric pylorus, and distinct from gastric intestinal
metaplasia. Gastric and intestinal cell lineages within
Barrett’s glands are clonal, indicating derivation from a
single stem cell.
Conclusions Barrett’s shows the proliferative and stem
cell architecture, and pattern of gene expression of
pyloric gastric glands, maintained by stem cells showing
gastric and intestinal differentiation: neutral drift may
suggest that intestinal differentiation advances with
time, a concept critical for the understanding of the
origin and development of Barrett’s oesophagus.
INTRODUCTION
Barrett’s oesophagus remains an enigma with no
agreement about its origin,1–3 and the nature of the
epithelium in Barrett’s mucosa is disputed,4 5 with
controversy regarding which epithelial component
progresses to cancer. The belief that intestinal meta-
plasia (or ‘specialised epithelium’), where goblet
cells are plentiful, is typically required for the diag-
nosis of Barrett’s oesophagus2 has lead to Barrett’s
mucosa being regarded as ‘intestinal metaplasia’,
and the mucosal units as ‘crypts’, resembling crypts
in the intestine. However, the phenotype of
Barrett’s oesophagus is protean containing a variety
of cell lineages. Even in ‘specialised epithelium’,
there are multiple cell lineages: columnar cells
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Signiﬁcance of this study
What is already known on this subject?
▸ Barrett’s glands are protean and contain a wide
range of differentiated cell lineages.
▸ Barrett’s glands are clonal and contain
multiple, multipotent stem cells.
▸ Dogma states that Barrett’s is a metaplasia of
the squamous oesophagus.
What are the new ﬁndings?
▸ The gene expression and proliferative
compartments of Barrett’s glands reﬂects that
of pyloric glands which also demonstrate
bidirectional migration, as seen in gastric
glands.
▸ The stem cell zone is located at the neck of
Barrett’s glands, similar to pyloric glands:
gastric and intestinal cell lineages within
Barrett’s glands show a common stem cell
origin.
▸ ‘Specialised’ gastric glands resemble pyloric
glands showing partial intestinalisation.
▸ The gastric gland architecture and organisation
is maintained in dysplasia.
How might it impact on clinical practice in
the foreseeable future?
▸ Endoscopic and pathological examination of
the gastric cardia may need to be more
rigorous in gastro-oesophageal reﬂux disease
patients.
▸ More investigation into determining glandular
phenotype as a biomarker of progression to
dysplasia in Barrett’s patients is needed.
▸ Any unifying proposal for the origin and
development of Barrett’s oesophagus should
explain their resemblance to pyloric glands.
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resembling gastric foveolar cells containing MUC1, MUC5AC
and mucus secreting cells expressing MUC6—mucin core pro-
teins characteristic of gastric epithelium,6 7 and goblet cells,
with MUC2 and MUC3—seen in intestinal epithelium.8 Thus,
the so-called ‘specialised epithelium’ of Barrett’s oesophagus,
often compared with intestinal metaplasia, shows evidence of
gastric lineage differentiation as well as intestinal differentiation.
Barrett’s mucosa contains several different types of glands—
Paull et al,9 by mapping the distribution of the several pheno-
types, reported a zonal distribution of the different types of
mucosa, with oxyntic-type glands with parietal and chief cells
or oxynto-cardiac glands interposed between the specialised col-
umnar epithelium and the lower oesophageal sphincter. Such
‘zonation’ has been replicated, although some reports10 11 have
found the different phenotypes randomly distributed through-
out Barrett’s mucosa. There is a gradient of goblet cell density,
with signiﬁcantly lower numbers seen in the distal Barrett’s
segment,10 correlated with an oesophageal luminal pH gradi-
ent.11 Cardiac mucosa is present throughout the segment, with
oxynto-cardiac mucosa more frequently found distally.9 10
Going et al,10 reported higher frequencies of cardiac and
oxynto-cardiac mucosa in the distal Barrett’s segment, with
several different mucosal phenotypes at any single anatomical
level, although ‘specialised’ epithelium was found at all levels.
Glands showing intestinalisation, resembling ‘complete type’
(Type I) intestinal metaplasia, characterised by the presence of
absorptive cells, Paneth cells, and goblet cells, are also seen.10
Thus, Barrett’s oesophagus contains multiple lineages and
glands with several phenotypes.
Human intestinal crypts and gastric glands are clonal popula-
tions—derived from a single tissue-speciﬁc stem cell.12 These
clonal crypts and glands contain multiple, multipotential stem
cells from which all the contained lineages derive: studies using
mitochondrial DNA (mtDNA) mutations that cause cytochrome
c oxidase (CCO) deﬁciency as clonal markers, showed Barrett’s
metaplastic glands as clonal units maintained by multiple stem
cells, and all epithelial cell lineages within a gland derived from
multipotential stem cells.13 Thus, whatever the complexity of a
Barrett’s gland, whatever heterogeneous cell lineages it contains,
it was derived from a single stem cell and that original stem
cell’s progeny has sufﬁcient multipotentiality to maintain its
multilineage habitus.
Barrett’s glands show evidence of gastric and intestinal differ-
entiation patterns: if such glands are clonal, the stem cell(s) will
show capacity to differentiate into gastric and intestinal cell
lineages. We show that specialised Barrett’s glands show
maximal proliferation in the middle part of the gland, that cells
migrate in a bidirectional manner and that the stem cell niche is
located in the middle part of the gland, resembling the gastric
gland and not the intestinal crypt. Region-speciﬁc gene expres-
sion supports a gastric gland plan, and we propose that Barrett’s
glands are maintained by stem cells with gastric and intestinal
differentiation capacity that progress to intestinal type over
time.
MATERIALS AND METHODS
Tissues: formalin-ﬁxed, parafﬁn-embedded archival non-
dysplastic Barrett’s oesophagus and Barrett’s dysplasia tissue spe-
cimens and frozen specimens were obtained from patients
undergoing oesophagectomy or endoscopic mucosal resection
for adenocarcinoma or dysplasia (n=34). Normal gastric and
intestinal metaplastic formalin-ﬁxed, parafﬁn-embedded speci-
mens were obtained from patients undergoing resection for
either gastric carcinoma or high-grade dysplasia (n=23).
Histological examination following standard H&E staining and
periodic acid Schiff/Alcian blue staining was carried out by at
least two qualiﬁed pathologists (RH, MR-J, MRN, NS or
NAW). Ethical approval was sought and obtained from the
London research ethics committee, Stanmore11/LO/1613.
Immunohistochemistry (IHC) was carried out using methods
described in online supplementary methods. The numbers of
Ki67+ and IdU+ cells were scored within Barrett’s glands as
follows: two tissue sections from each of the patients were
included and three areas of approximately 100 cells were scored
per section. For cell counts, glands were divided into three
equal regions: the bottom third was designated the gland base-
corresponding to the Muc6+/trefoil family factor 2 (TFF2)+
mucus secreting zone, and the remaining upper two-thirds of
the gland were divided equally and designated the middle
region and the surface of the gland, respectively (highlighted in
ﬁgure 1A).
In situ hybridisation (ISH) was carried out using the methods
described in online supplementary methods.
Clinical protocol for labelling with iododeoxyuridine (IdU):
The Stem Cell Assessment In Neoplastic Tissues (SAINT) trial
(n=4 patients) was approved by the Leicestershire Ethics Board
Ref Number: 09122, Medicines Health Regulatory Authority
Number: CTA 21275 and Research Ethics Committee Number:
7213 as previously described.14 Prior to oesophagectomy,
oesophageal Barrett’s adenocarcinoma patients were infused
with IdU, and details are given in online supplementary
methods.
Laser capture microdissection and PCR sequencing of MtDNA:
This was carried out using the methods described in online sup-
plementary methods.
RESULTS
Proliferative organisation in Barrett’s glands
Ki67+ cells were concentrated in the middle region of Barrett’s
gland with fewer proliferating cells at the surface of the glands,
little at the bases and none in the very basal cells (ﬁgure 1A,
and online supplementary ﬁgure S1). This pattern of expression
was consistent throughout all study patients. The majority of
Ki67+ cells were seen within the middle region of the gland in
all patients (54.5% of total cells). The percentage of Ki67+
cells within the middle region was shown to be signiﬁcantly
greater than that of the base of the gland and the gland surface
within these patients (Kruskal-Wallis one-way analysis of vari-
ance, p<0.05).
Cell migration in Barrett’s glands
At 7 days postinjection, IdU+ cells were seen towards the base
and middle of the gland and also at the surface (ﬁgure 1B), clus-
tered together in these gland segments. At 11 days, IdU+ cells
were seen in the base of the gland, in the middle and also at the
surface of the gland, but the number of IdU+ cells was reduced
compared to 7 days with the majority of positive cells seen
towards the gland bases (ﬁgure 1B) suggesting that the superﬁ-
cial labelled cells have been rapidly lost into the lumen, with
only a few still migrating, but that migration towards the base is
slower. At 29 days after injection, IdU+ cells were still evident,
although greatly reduced compared to 11 days, and were seen
almost exclusively in the bases of the glands, where a few cells
were still evident at 67 days after injection1.4
The distribution of IdU+ cells within Barrett’s glands over
time was quantiﬁed as described above: ﬁgure 1C shows the dis-
tribution of IdU+ cells in Barrett’s glands with time after IdU
injection. After 7 days, 4.45% of IdU+ cells were observed
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within the surface of the gland, although labelled cells were still
numerous within the middle region (3.65%). However, fewer
IdU+ cells were observed within the gland base (1.74%). After
11 days, IdU+ cells were still observed within the surface of the
glands, although the fraction had signiﬁcantly reduced and they
now represented 0.07% of total cells. The highest percentage
was observed within the base of the Barrett’s gland (1.36%).
After 29 days chase, the number of IdU+ cells was signiﬁcantly
reduced compared to 11 days, and were exclusively observed
within the base of the Barrett’s glands (0.181% of total cells).
Furthermore, the number was reduced again after 67 days
chase: at this time IdU+ cells were seen exclusively within the
base of the gland (0.07%).
Taken together with the Ki67 labelling index distribution,
which shows that the bases of Barrett’s glands contain few
labelled cells (see online supplementary ﬁgure S1), and since
maximal cell proliferation is present in the middle of the gland,
cells migrate faster towards the surface or foveolar portion of
the gland, and slowly into the base of the gland. Labelled cells
in Barrett’s glands show bidirectional ﬂux.
In corpus gastric glands, one tissue section from each patient
was included and three areas of over 100 cells within each
region of the gastric unit (foveolus or pit, isthmus/neck and
gland base) and were scored per slide. Online supplementary
ﬁgures S2A,B show that Ki67-labelled cells occur mainly within
the neck/isthmus regions of the gastric unit (15.2% of total
cells) with fewer Ki67+ cells observed within the foveolus
(9.5%) and 1.5% in the gland base. A similar distribution is
shown in gastric antral mucosa (see online supplementary ﬁgure
S2B). After 7 days, the highest percentage of IdU+ cells was
observed within the foveolar region (3.3%) (see online supple-
mentary ﬁgures S2C,D), whereas at 11 days, the highest per-
centage of cells was observed within the neck (0.27%) (see
online supplementary ﬁgures S2E,F). There was a signiﬁcant
Figure 1 (A) (i) H&E (highlighted with s(surface), m(middle) and b(base)) and (ii) showing Ki67 expression in Barrett’s glands; (iii) The number of
Ki67+ cells in each region of Barrett’s glands; (B) (i) IdU+ cells in the base, middle and surface of Barrett’s glands 7 days. Inserts show high-power
images of IdU+ cells; (ii) IdU+ cells at 11 days (arrowed). Inserts show a high-power image of IdU+ cells. (C) The changes in the distribution of IdU
+ cells Barrett’s glands with time after IdU injection. (i) IdU+ cells within the foveolus of the gland rapidly disappear and cannot be identiﬁed after
11 days; (ii) IdU+ cells identiﬁed within the middle of the gland decrease more rapidly after 11 days; (iii) the incidence of IdU+ cells in the base of
Barrett’s glands falls slowly up to 67 days after infusion.
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reduction in IdU+ cells within the neck and the foveolar
regions between 7 and 11 days, suggesting that cellular ﬂux
occurs mainly in the foveolus, since 7 days postinjection most
IdU+ cells are identiﬁed within this region. Most cells are lost
into the lumen after 11 days, yet some cells remain within the
neck region of the gland. However, IdU-labelled parietal cells
were seen towards the bases of gastric glands at 67 days after
infusion of IdU14.
Cell ﬂux is bidirectional in Barrett’s glands, similar to that
seen in gastric glands.
The stem cell niche in Barrett’s glands
Here, stem cells were identiﬁed by ISH for the established
gastrointestinal epithelial stem cell marker LGR5.15 Figure 2
shows the distribution of cells which express LGR5 mRNA in
Barrett’s glands (A, B), in pyloric glands (C, D) and in the
crypts of gastric intestinal metaplasia (C, F). Figures are repre-
sentative of n=5. In the pyloric glands (ﬁgure 2C,D) LGR5
mRNA is seen quite widely distributed in the isthmus/neck area
of the glands, while the foveola and the mucin-secreting bases
of the glands are negative. In Barrett’s glands (ﬁgure 2A,B)
LGR5 mRNA is localised in the middle of the gland, corre-
sponding to the equivalent of the isthmus/pit in a pyloric gland.
Figures 2E and F show that in intestinal metaplasia in the
stomach, LGR5 mRNA is found at the bases of the crypts,
similar to colonic crypts (see online supplementary ﬁgure S3).
The stem cell niche in Barrett’s oesophagus is localised in the
middle of the gland, in the equivalent of the isthmus/pit of a
pyloric gland, as seen in pyloric gastric glands. In gastric intes-
tinal metaplasia, the stem cell niche is at the base of the crypt,
comparable with the colon.
Clonal organisation of Barrett’s glands
Figure 3 shows a well-orientated Barrett’s gland (H&E ﬁgure 3A)
stained with anti-MUC5AC and anti-MUC2 (ﬁgure 3B pre-laser
capture microdissection (LCM), ﬁgure 3C post-LCM,): cells
microdissected from the gland all contain the same heteroplas-
mic m.825 G>T mutation in the MT-RNR1 gene. MUC2+
cells (ﬁgure 3Dii), MUC5AC+ cells (ﬁgure 3Diii) and basal
mucus-secreting cells (ﬁgure 3Div) all share this mutation, but
cells from a neighbouring gland do not (ﬁgure 3Di). Online
supplementary ﬁgure S4 shows high-power views of the cells
dissected.
Gene expression in Barrett’s glands
Figure 4Ai shows that appropriately sectioned Barrett’s glands
appear slender and elegant, with a single surface opening or
foveolus, and about half-way down the gland divides into a
number of basal tubules, similar to the disposition of the gastric
gland.12 The upper part of the gland contains columnar cells
that stain with D/PAS and Alcian Blue, and there are also
numbers of alcianophilic, sialomucin-containing goblet cells and
non-goblet cells. In the base of the gland, there is an area, of
variable size, which contains D/PAS+ mucous cells only. The
proliferative zone (Ki67+) in this gland is seen above this area,
extending into the upper part of the gland (ﬁgure 4Aii), similar
to that seen in gastric glands (ﬁgure 4Aiii).
In Barrett’s glands and pyloric glands, MUC5AC is seen exclu-
sively in the upper part of the gland, decreasing in intensity as the
stem cell zone, delineated by LGR5 mRNA expression, is reached
(ﬁgure 4Aiv and Bi respectively). MUC6 expression in Barrett’s
and pyloric glands is conﬁned to the mucous cells at the base of
the glands below the LGR5 mRNA zone (ﬁgure 4Bii and iii).
MUC2 shows a tight distribution throughout the upper part of the
Barrett’s gland, concentrated but not conﬁned to the goblet cells,
diminishes in expression towards the LGR5 zone, and is absent
from the MUC6+ bases (ﬁgure 4Biv). MUC2 is absent from the
pyloric epithelium (see online supplementary ﬁgure S5A). TFF1
protein and mRNA is located in the upper part of Barrett’s and
pyloric glands, coexpressed with MUC5AC (ﬁgure 4Ci, ii and iii,
respectively, and see online supplementary ﬁgure S5B). TFF2 is
seen conﬁned largely to the MUC6+ cells in the base of Barrett’s
and pyloric glands (ﬁgure 4Civ, Di and ii, respectively, and see
online supplementary ﬁgure S5C). TFF2 mRNA is also present in
low concentration in the foveolar equivalent of the Barrett’s gland
(ﬁgure 4Di, arrow). TFF3 protein is expressed throughout the
Barrett’s gland, concentrated in the goblet cells in the upper part
of the gland (ﬁgure 4Diii), conﬁrmed by the distribution of TFF3
mRNA (ﬁgure 4Div). TFF3 is absent from the pyloric mucosa,
unless intestinal metaplasia is present (see online supplementary
ﬁgure 5Di and ii). In total, 15 patients with Barrett’s metaplasia
and 15 normal stomachs taken outside the resection margins of
patients with gastric adenocarcinoma were used. All results
described were observed in all samples.
The pattern of gene expression in antral or pyloric mucosa is
thus reﬂected in Barrett’s glands.
Cell proliferation and gene expression in Barrett’s dysplasia
Figure 5 shows the distribution of Ki67+ cells, mucin core pro-
teins and TFFs in low-grade Barrett’s dysplasia (ﬁgure 5A
Figure 2 LGR5 mRNA expression using in situ hybridisation. (A, B) A bright ﬁeld image and accompanying dark ﬁeld image of LGR5 mRNA in
Barrett’s glands; (C and D) A bright ﬁeld image and accompanying dark ﬁeld image of LGR5 mRNA of pyloric gastric glands; (E and F) A bright ﬁeld
image and accompanying dark ﬁeld image of LGR5 mRNA in gastric intestinal metaplasia.
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H&E): the proliferative organisation mirrors that seen in
Barrett’s glands and, thus, in gastric glands, with preservation of
the non-proliferative MUC6+/TFF2+ cells at the base of the
gland. Figure 5B shows that the proliferative zone indicated by
Ki67 expression expands towards the top of the glands, while
the bases remain largely non-proliferative. MUC2 is present in
the middle and top of the glands (ﬁgure 5C) and MUC5AC on
the surface and in the middle of glands (ﬁgure 5D): the basal
TFF2+/MUC6+ mucous zone is preserved (ﬁgure 5E and F).
LGR5 mRNA+ cells are seen again above the MUC6+/TFF2+
cells, but there is some expansion of the zone towards the
surface (ﬁgure 6Ai–Cii). These data are representative of 15
Barrett’s dysplasia specimens. In Barrett’s carcinoma (ﬁgure 6Di
and ii) LGR5 mRNA shows a speciﬁc localisation at the bases of
the malignant glands (n=5).
Gene expression in gastric intestinal metaplasia (IM)
In gastric intestinal metaplasia, especially in the so-called
‘mixed’, there is expression of gastric and intestinal mucins.16
Similarly, in partially intestinalised gastric glands, the distribu-
tion of the TTFs follows the pattern seen in Barrett’s glands (see
online supplementary ﬁgure S6). TFF2 and MUC6 (see online
supplementary ﬁgure 6A, D) is seen at the bases, in continuity
with goblet cell-containing intestinalised glands. TFF1 mRNA is
seen at the apices of such partially intestinalised glands (see
online supplementary ﬁgure S6B), even where goblet cell differ-
entiation is clearly seen (arrow). TFF2 mRNA is concentrated in
the gland base (see online supplementary ﬁgure S6C), although
as in Barrett’s glands (ﬁgure 4, white arrow), it is also seen in
the goblet cell-containing surface (black arrow). TFF3 mRNA is
seen throughout the gland (ﬁgure 6E), but prominent in surface
goblet cells (arrow). LGR5 mRNA expression becomes localised
in the isthmus/neck equivalent in dysplastic glands (see online
supplementary ﬁgure S6Fi and ii), and the basal MUC6+/TFF2+
zone is preserved (arrowed).
DISCUSSION
The gland pattern of Barrett’s glands is that of glands of the
pyloric mucosa: the proliferative zone is housed within the
isthmus/neck equivalent of the gland, and cell migration is bidir-
ectional, upwards into the foveolus equivalent, and downwards
into the tubules of the gland base. The stem cell zone, as indi-
cated by the presence of LGR5 mRNA+ cells, is located in the
lower part of this area, almost at the level of the D/PAS+, TFF2+,
Figure 3 A well-orientated Barrett’s gland. (A) An H&E; (B and C) stained with MUC5AC and MUC2 (ﬁgure 3B prelaser capture microdissection
(LCM), ﬁgure 3C post-LCM). (D) Cells microdissected from the gland all contain the same heteroplasmic m.825 G>T mutation in the MT-RNR1 gene.
MUC2 cells (i) wild-type cells; (ii) MUC2 cells, (iii) MUC5AC cells, (iv) basal mucous-secreting cells (note: a lower level of heteroplasmy was
detected), (iv) all share this mutation, but cells from the neighbouring wild-type gland do not. Online supplementary ﬁgure S4 shows high power
views of the cells dissected.
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MUC6+ cells (ﬁgure 4), while LGR5 mRNA+ cells in the
antral glands are seen mainly in the isthmus/neck. MUC5AC
and TFF1 are found in the upper part of the gland, while TFF2
and MUC6 concentrated in the D/PAS cells at the gland base, as
seen in antral gastric glands. MUC2, and to a lesser extent
TFF3, is seen predominantly in goblet cells in the upper part of
the gland. The organisation of Barrett’s glands, their prolifera-
tive architecture, stem cell localisation and patterns of gene
expression, directly reﬂects the pyloric gastric gland. We con-
clude that Barrett’s glands contain equivalents of the foveolus,
isthmus, neck and base seen in gastric glands.
The distribution of Ki67+ cells has been studied in Barrett’s
glands previously, and similar patterns seen to those described
herein, persist even in dysplasia.17 The dynamic aspects of cell
migration have not been studied: it should be recalled that Ki67
labels all cells in the cell cycle and the distribution seen in ﬁgure 1
Figure 4 Gene expression in
Barrett’s glands compared with pyloric
glands. Well-orientated glands
displaying a contiguous surface,
middle and base were analysed.
(A) (i) Barrett’s stained with D/PAS/
Alcian Blue; (ii) Ki67 protein expression
in Barrett’s glands; (iii) in pyloric
glands; (iv) MUC5AC protein
expression in Barrett’s glands.
Figure 4B (i) MUC5AC protein
expression in pyloric glands; (ii) MUC6
protein expression in Barrett’s glands;
(iii) in pyloric glands; (iv) MUC2
expression in Barrett’s glands (see
online supplementary ﬁgure S5A
shows MUC2 to be absent from pyloric
glands); ﬁgure 4C (i) TTF1 protein and
(ii) mRNA expression in Barrett’s
glands; (iii) trefoil family factor 1
(TFF1) mRNA expression in pyloric
glands. Supplementary ﬁgure 5B
shows MUC5AC protein also in the
upper part of pyloric glands; (iv) TTF2
protein in Barrett’s glands. Figure 4D
(i) mRNA expression in Barrett’s
glands; (ii) TFF2 mRNA in pyloric
glands; (iii) TFF3 protein and (iv)
mRNA in Barrett’s glands.
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reﬂects the distribution of cycling cells, effectively at time 0. IdU
labels cells only in the S phase, and earlier readings available at
7 days would then reﬂect the position of cells labelled 7 days previ-
ously (note that the very basal gland is devoid of Ki67+ cells: see
online supplementary ﬁgure S1). The fraction of IdU+ cells
labelled in the foveolar region now equals that seen in the erst-
while proliferative zone. This means that cells have migrated, fairly
rapidly, upwards to the foveolus. In the base, there are, at this
time, relatively few labelled cells, indicating that migration to the
base is slower. At 11 and 29 days, while labelled cells are lost from
the foveolar region (by extrusion from the surface), and from the
proliferative zone, labelled cells remain in the base, and by
67 days, only the base contains any labelled cells.
Migration in Barrett’s glands is bidirectional: the detailed
studies of Hattori and Fujita18 in the hamster corpus and
pylorus have shown that, while cells migrate to the surface in
some 14 days, over 300 days are needed to reach the corpus
gland base. In humans, foveolar cells migrate to the surface
rapidly (see online supplementary ﬁgure S1), but labelled par-
ietal cells are seen in the isthmus at 67 days after IdU injec-
tion,14 indicating that in the human being, a similar lengthy
period is needed for cells to reach the gland base, conﬁrming
bidirectional ﬂux.
LGR5 has been shown to be a true stem cell marker in the
mouse by lineage labelling.15 LGR5+ cells represent a stem-like
cell population in colon carcinomas, which are also found in the
bases of crypt-like structures within the tumour that resembles
normal crypts19 (and see ﬁgure 6D). The presence of LGR5+
cells and all differentiated lineages within colon carcinomas20
and adenomas has been reported,19 suggesting that LGR5
detects stem cell populations in human epithelia. LGR5 mRNA
localises speciﬁcally to the junction between the TFF1
+/MUC5AC+/MUC2+ cells and the basal TFF2+/MUC6+
cells, and represents the stem cell zone, or niche, of Barrett’s
glands. Cells, including the MUC2+ cells destined to be goblet
cells, migrate upwards from here, while the TFF2+/MUC6+
cells migrate downwards. In pyloric glands, LGR5 is also loca-
lised in the isthmus/neck region, and a similar pattern of gene
expression is seen. Contrast these ﬁndings with those exhibited
in gastric intestinal metaplasia (ﬁgure 2E,F): LGR5 mRNA is
seen in the base, as in the small intestinal crypt (see online sup-
plementary ﬁgure S3) and colonic crypts.19 Barrett’s carcinoma
glands show LGR5 mRNA localisation very similar to that
described by Merlos-Suarez et al20 (ISH was used as IHC for
human LGR5 is unreliable) (ﬁgure 6D).
There have been previous studies of the distribution of mucin
gene expression6 21 and also of TFFs22 23 in Barrett’s glands:
selective segregation of MUC5AC with TFF1 and MUC6 with
TFF2 is seen in Barrett’s glands, mirroring antral gastric
glands.24 TFF3 is usually colocalised with MUC2, but in
Figure 5 Protein expression in low-grade Barrett’s dysplasia. (A) An H&E; (B) Ki67 expression: (C) MUC2 expression; (D) MUC5AC expression;
trefoil family factor 2 (TFF2); (E) and MUC6 (F) colocalise in the mucous cell bases of the gland, which remain in dysplasia.
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Barrett’s glands, it is expressed in the MUC6+/TFF2+ basal
mucous cells, differing from antral glands and also in incom-
pletely intestinalised intestinal metaplastic glands (see online
supplementary ﬁgure S6E). TFF3 expression has been described
in the normal human stomach,25 although in our hands not
unless intestinal metaplasia is present (see online supplementary
ﬁgure S5D). TFF2 mRNA is also expressed, in low concentra-
tion, in the ‘foveola’ of Barrett’s and partially intestinalised
gastric glands (see ﬁgures 4Di, ii and also online supplementary
ﬁgure S6C).
An intriguing point is the relationship of Barrett’s metaplasia
to intestinal metaplasia.26 ‘Mixed’ intestinal metaplasia occurs
in the stomach,16 and online supplementary ﬁgure S6 shows
that such mixed types of intestinal metaplasia show a similar
pattern of TFF expression as Barrett’s glands—the mucin histo-
chemical proﬁles also show a mixed pattern,16 suggesting that
Barrett’s glands resemble the mixed metaplastic glands seen in
the stomach.
Barrett’s glands are clonal populations13 (ﬁgure 3).
Established Barrett’s glands contain multiple cell lineages,
MUC5AC+/TFF1+, MUC2+ and MUC6+/TFF2+, and in
Barrett’s epithelium, gastric and intestinal endocrine cells are
found.27 The stem cell niche in the isthmus/neck equivalent area
of the gland contains stem cells capable of delivering all these
lineages. Either the niche contains unique stem cells capable of
giving rise to all contained lineages, or the niche is composed of
a mixture of stem cells with limited repertoire, for example,
limited to TFF1+/MUC5AC+ and TFF2+/MUC6+ lineages,
and other stem cells give rise to the TFF3+/MUC2+ lineage
(ﬁgure 7).
The implication here is that Barrett’s glands were originally
gastric glands containing TFF1+/MUC5AC+ and TFF2
+/MUC6+ lineages. The homeobox gene, CDX2, is associated
with activation of intestinal differentiation.2 This occurs in the
stomach as a result of Helicobacter pylori infection, and could
occur in Barrett’s glands as a result of continued bile/acid
Figure 6 LGR5 mRNA expression in Barrett’s dysplasia and carcinoma. (A-C) low- (i) and high-power (ii) images showing non-isotopic ISH for
LGR5 mRNA localisation in Barrett’s dysplasia; (D) (i) bright ﬁeld image and accompanying dark ﬁeld image (ii) of isotopic ISH for LGR5 mRNA
localisation in invasive Barrett’s carcinoma glands.
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reﬂuxate. CDX2 expression in a stem cell will induce progenitors
of the TFF3+/MUC2+ lineage. Most stem cell divisions are sym-
metrical, and neutral drift governs stem cell dynamics:28 stochas-
tically, a TFF3+/MUC2+ stem cells may survive in the niche,
and the gland then contains the ﬁrst stem cell committed to intes-
tinal differentiation. Neutral drift dynamics would predict that
such a stem cell could be lost, and the gland maintains its gastric
phenotype, but the stem cell could expand in the niche, giving
the Barrett’s phenotype of mixed gastric and intestinal lineages.
Eventually, niche succession would ﬁll the niche with MUC2
+/TFF3+ stem cells, giving a fully intestinalised gland, seen in
Barrett’s oesophagus.9 10 We would state that causality cannot be
inferred from the observational data provided. Gastric intestinal
metaplasia may also go through such a transitional phase16 (see
online supplementary ﬁgure S6). Cells expressing gastric and
intestinal markers are seen, possibly the progeny of stem/progeni-
tor cells where CDX2 is only partially activated, and where
gastric and intestinal gene expression coexists.
The gland pattern, including the basal TFF2+/MUC6+ cells,
are preserved in dysplasia, with dysplastic cells conﬁned to the
upper part of the gland; in gastric carcinoma, the dysplastic cells
may originate in the deep pit or isthmus of the gastric gland:29
in Barrett’s oesophagus, the dysplastic part of the gland is clonal
for p16 mutations even when the surface cells lack dysplastic
features.30 It is not yet known if this is true also for the basal
TFF2+/MUC6+ basal mucous cells. Dysplasia and indeed car-
cinoma can show gastric and intestinal differentiation markers.7
Dysplasia may arise through mutational events in stem cells:
hence, dysplasia developing in TFF1+/MUC5AC+ or in TTF3
+/MUC2+ committed stem/progenitor cells may account for
the origin of the dysplasia in the stem cell zone and also for the
several differentiation patterns described.7
Barrett’s segments may develop from upward progression of
the cardiac mucosa, a concept which appears to have fallen out
of favour in recent years in favour of a metaplastic origin from
oesophageal squamous epithelium.2 But there is older evidence,
such as the development of neo-Barrett’s after subtotal oesopha-
gectomy and reconstruction with a gastric conduit: about 50%
of these patients develop columnar epithelium in the area lined
by squamous mucosa at the time of the procedure, and the
length of columnar mucosa increases with longer follow-up.31
Recent evidence from animal models,1 and from following the
progression of metaplasia at the cardia,32 is supportive of such a
proposal. Whichever theory is entertained, it will have to
account for the observation that Barrett’s glands replicate the
organisation of gastric glands.
Figure 7 (A) An H&E of a well-orientated Barrett’s glands with diagrammatic representation of a model of organisation in Barrett’s glands; the
stem cell zone, here visualised as a ring of 6–7 cells, occupies the centre of the gland immediately above the point of branching. The trefoil family
factor 1 (TFF1)+/MUC5AC+/MUC2+ cells migrate upwards from this zone while the TFF2+/MUC6+ cells migrate towards the base. (B, C) Possible
models for stem/committed progenitor lineage relationships in Barrett’s glands. Two possibilities are shown: (B) where a single stem cell gives rise
to committed progenitors for the TFF1+/MUC5AC+ cells, the TFF3+/MUC2+ cells and the TFF2+/MUC6+ cells. (C) A neutral drift model where there
are stem cells which produce TFF2+/MUC6+ cells, and stem cells which produce TFF1+/MUC5AC+ cells: following an event such as activation of
CDX2, this stem cell(s) commit to produce TFF3+/MUC2+ cells, and stochastic niche succession will eventually, in some glands, move entirely to a
niche containing stem cells committed to the TFF3+/MUC2+ lineage. We propose a conversion from non-goblet containing columnar to a
specialised epithelium and ﬁnally to intestinal metaplasia.
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